Glass House Brands (GLAS) Other Non Operating Income (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Other Non Operating Income of -$409000.0 for Q1 2026, up 29.97% quarter-over-quarter from -$584000.0 in Q4 2025.
Glass House Brands (GLAS) Other Non Operating Income (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Other Non Operating Income for 7 consecutive years, with -$409000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income changed N/A year-over-year to -$409000.0; the TTM figure through Mar 2026 stood at -$629000.0 (changed N/A YoY), while the FY2025 annual figure was -$292000.0, changed N/A from the prior year.
- Other Non Operating Income rose to -$409000.0 in Q1 2026 per GLAS's latest filing, from -$584000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1128.8 billion in Q2 2023 and bottomed at -$584000.0 in Q4 2025.
- Historically, Other Non Operating Income has averaged $84.2 billion across 5 years, with a median of $42000.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Non Operating Income soared 32163536.36% — and 2024, when it plunged 750.71%.
- Glass House Brands' Other Non Operating Income stood at $48000.0 in 2022, then jumped by 306.25% to $195000.0 in 2023, then tumbled by 116.41% to -$32000.0 in 2024, then slumped by 1725.0% to -$584000.0 in 2025, then gained by 29.97% to -$409000.0 in 2026.
- Business Quant data shows GLAS's Other Non Operating Income at -$409000.0 in Q1 2026, -$584000.0 in Q4 2025, and $36000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Glass House Brands | 835.49 Mn | 816.93 Mn | 15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -409,000.00 |
| Dec 31, 2025 | -584,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 328,000.00 |
| Jun 30, 2024 | -32,000.00 |
| Mar 31, 2024 | -112,524.00 |
| Dec 31, 2023 | 195,000.00 |
| Sep 30, 2023 | 466,411.00 |
| Jun 30, 2023 | 1,128.84 Bn |
| Mar 31, 2023 | -13,227.00 |
| Dec 31, 2022 | 48,000.00 |
| Sep 30, 2022 | 424,010.00 |
| Jun 30, 2022 | 49.53 Bn |
| Mar 31, 2022 | 16,105.00 |
| Dec 31, 2021 | -174,560.00 |
| Sep 30, 2021 | 97.86 Bn |
| Jun 30, 2021 | 154,000.00 |
| Mar 31, 2021 | -671,000.00 |
| Dec 31, 2020 | -2.11 Mn |
| Sep 30, 2020 | 988,898.00 |